2nd potential Alzheimer's drug can slow disease by a few months but with safety risk

Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening by about four to seven months, according to researchers.

FILE - A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

13WHAM /  🏆 256. in US

México Últimas Noticias, México Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Leer más »

Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Leer más »

Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Leer más »

Gene-Editing Tools Pave Way for New Alzheimer's TreatmentsTwo new studies using CRISPR gene editing offer potential new treatments for Alzheimer's disease.
Leer más »